T cell receptor alpha variable 34Genealiases: TCRAV26S1 · TCRAV34S1
Q-omics provides the consensus-scored TRAV34 profile across patient tissues and cancer cell-line models. TRAV34 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TRAV34 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TRAV34 RNA expression shows 11,323 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KIRC, and THYM as cancer lineages where TRAV34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV34 survival associations across molecular data types. TRAV34 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV34 RNA expression–survival associations across cancer types. High TRAV34 expression shows favorable associations in BLCA, LUAD, CESC, SKCM, HNSC and LAML. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TRAV34 RNA expression.
This table summarizes TRAV34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV34 shows lower tumor expression in COAD and LUAD and higher tumor expression in KIRC, BRCA, BLCA and KIRP. The KIRC box plot shows higher TRAV34 RNA expression in tumor versus normal tissue (log2 FC = +0.422, t-test p < 0.001).
This table shows molecular features associated with TRAV34 in patient tissues and cancer cell lines. In patient samples, TRAV34 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
